| Literature DB >> 23383055 |
Cecilia Berg1, Tobias Backström, Svante Winberg, Richard Lindberg, Ingvar Brandt.
Abstract
The selective serotonin reuptake inhibitor (SSRI) fluoxetine (FLU, Prozac®) is commonly prescribed for depression in pregnant women. This results in SSRI exposure of the developing fetus. However, there are knowledge gaps regarding the impact of SSRI exposure during development. Given the role of serotonin in brain development and its cross-talk with sex hormone function, we investigated effects of developmental exposure to pharmacologically relevant concentrations of FLU (3 and 30 nM (measured)) on brain neurotransmitter levels, gonadal differentiation, aromatase activity in brain and gonads, and the thyroid system, using the Xenopus tropicalis model. Tadpoles were chronically exposed (8 weeks) until metamorphosis. At metamorphosis brains were cryosectioned and levels of serotonin, dopamine, norepinephrine, and their metabolites 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylacetic acid, and homovanillic acid were measured in discrete regions (telencephalon, hypothalamus and the reticular formation) of the cryosections using high-performance liquid chromatography. Exposure to 30 nM FLU increased the concentration of 5-hydroxyindoleacetic acid in hypothalamus compared with controls. FLU exposure did not affect survival, time to metamorphosis, thyroid histology, gonadal sex differentiation, or aromatase activity implying that the effect on the serotonergic neurotransmitter system in the hypothalamus region was specific. The FLU concentration that impacted the serotonin system is lower than the concentration measured in umbilical cord serum, suggesting that the serotonin system of the developing brain is highly sensitive to in utero exposure to FLU. To our knowledge this is the first study showing effects of developmental FLU exposure on brain neurochemistry. Given that SSRIs are present in the aquatic environment the current results warrant further investigation into the neurobehavioral effects of SSRIs in aquatic wildlife.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23383055 PMCID: PMC3557231 DOI: 10.1371/journal.pone.0055053
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Monoamine concentration and ratios of metabolite to parent monoamine in three different brain regions of Xenopus tropicalis frogs at completed metamorphosis, after developmental chronic exposure to 0, 3 or 30 nM fluoxetine (Control, 3 FLU, and 30 FLU) in duplicate tanks (A and B).
| NE (µg/gprotein) | DOPAC (µg/g protein) | 5-HIAA (µg/g protein) | HVA (µg/gprotein) | DA (µg/g protein) | 5-HT (µg/gprotein) | DOPAC/DA *10−3 | HVA/DA * 10−3 | 5-HIAA/5-HT * 10−3 | |
|
| |||||||||
| Control A | 3.51±1.40 (6) | 2.19±1.30 (6) | 2.54±2.21 (6) | 1.94±0.39 (6) | 12.62±16.04 (6) | 6.06±4.34 (6) | 477±614 (6) | 329±224 (6) | 410±349 (6) |
| Control B | 8.64±5.22 (4) | 9.07±10.18 (4) | 8.00±7.14 (4) | 2.70±3.58 (4) | 56.91±67.70 (4) | 17.78±18.82 (4) | 406±691 (4) | 66±52 (4) | 695±558 (4) |
| 3 FLU A | 3.63±2.22 (6) | 1.49±1.26 (6) | 3.23±2.35 (6) | 2.11±1.23 (6) | 16.35±9.21 (6) | 15.29±14.57 (6) | 139±152 (6) | 272±372 (6) | 469±465 (6) |
| 3 FLU B | 5.94±4.86 (5) | 3.61±3.07 (6) | 3.15±1.23 (6) | 2.60±2.03 (6) | 18.35±10.30 (6) | 8.10±8.96 (6) | 215±141 (6) | 242±288 (6) | 1760±1669 (6) |
| 30 FLU A | 4.38±3.88 (5) | 1.19±0.81 (5) | 10.31±15.13 (6) | 1.92±1.69 (6) | 17.98±13.25 (6) | 22.54±33.12 (6) | 149. ±114 (5) | 222±251 (6) | 1080±1475 (6) |
| 30 FLU B | 6.70±5.85 (8) | 8.47±11.93 (8) | 15.63±34.05 (8) | 3.25±3.01 (8) | 31.28±30.43 (8) | 14.45±15.10 (8) | 407±696 (8) | 145±85 (8) | 1037±1241 (8) |
|
| |||||||||
| Control A | 4.84±4.88 (6) | 7.58±9.20 (6) | 3.19±3.00 (6) | 3.25±2.76 (6) | 13.56±16.10 (6) | 17.19±23.60 (6) | 607±443 (6) | 354±207 (6) | 474±491 (6) |
| Control B | 3.75±2.06 (5) | 2.22±1.35 (5) | 4.07±4.72 (5) | 1.26±0.64 (5) | 14.85±7.45 (5) | 6.94±7.45 (5) | 1966±169 (5) | 96±61 (5) | 876±908 (5) |
| 3 FLU A | 2.65±2.19 (6) | 2.63±2.25 (6) | 3.51±0.53 (6) | 2.14±0.94 (6) | 15.37±15.65 (6) | 12.39±11.50 (6) | 272±248 (6) | 330±395 (6) | 542±413 (6) |
| 3 FLU B | 5.84±5.00 (6) | 7.14±4.52 (6) | 4.00±3.11 (6) | 1.69±0.65 (6) | 22.66±19.25 (6) | 9.33±10.32 (6) | 570±669 (6) | 144±151 (6) | 1461±1300 (6) |
| 30 FLU A | 4.48±3.00 (8) | 10.67±13.47 (8) | 7.95±6.29 (8) | 1.62±1.07 (8) | 18.11±10.94 (8) | 22.12±21.93 (8) | 592±480 (8) | 100±58 (8) | 448±270 (8) |
| 30 FLU B | 4.56±2.49(7) | 4.94±4.11 (8) | 12.87±20.78 (8) | 10.65±17.83 (8) | 42.90±79.34 (8) | 22.50±42.92 (8) | 321±281 (8) | 284±250 (8) | 836±476 (8) |
|
| |||||||||
| Control A | 12.85±26.12 (6) | 4.93±3.64 (6) | 7.81±13.60 (6) | 3.05±1.41 (6) | 16.70±27.71 (6) | 13.66±18.13 (6) | 922±1099 (6) | 445±313 (6) | 1751±2957 (6) |
| Control B | 4.14±2.37 (6) | 9.75±13.44 (6) | 9.51±14.11 (6) | 3.38±2.73 (6) | 29.38±24.32 (6) | 15.55±25.38 (6) | 429±428 (6) | 284±447 (6) | 1871±2321 (6) |
| 3 FLU A | 8.47±10.42 (6) | 8.07±12.91 (6) | 7.46±8.30 (6) | 3.95±3.26 (6) | 48.74±77.08 (6) | 24.19±35.39 (6) | 529±664 (6) | 559±901 (6) | 385±202 (6) |
| 3 FLU B | 2.85±2.70 (5) | 7.19±7.52 (5) | 3.94±3.12 (5) | 1.43±0.88 (5) | 8.46±2.93 (5) | 7.15±6.80 (5) | 1042±1362 (5) | 219±188 (5) | 771±832 (5) |
| 30 FLU A | 2.11±1.447 (7) | 6.54±6.45 (7) | 3.30±4.81 (7) | 1.24±0.64 (7) | 11.49±14.92 (7) | 5.18±8.63 (7) | 807±972 (7) | 316±398 (7) | 6574±14693 (7) |
| 30 FLU B | 2.34±1.11 (8) | 10.69±13.89 (8) | 3.62±4.14 (8) | 2.61±0.95 (8) | 17.04±23.00 (8) | 6.28±9.61 (8) | 707±721 (8) | 325±186 (8) | 1760±2566 (8) |
Values represent mean ± SD (n).
Abbreviations: Norepinephrine (NE), 3,4-dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), dopamine (DA), and serotonin (5-HT).
Figure 1Concentration of 5-HIAA in the hypothalamus of Xenopus tropicalis at metamorphosis after developmental chronic exposure to fluoxetine at two different concentrations, 3 nM FLU (grey bar) and 30 nM FLU (black bar) and in controls (C, white bar).
Values represent mean ± SEM. Different superscript letters indicate significant differences between exposure groups (P<0.05, Tukey post hoc). n = 12−18.
Aromatase activity (mean ± SD) in gonads and brain of Xenopus tropicalis at completed metamorphosis after developmental chronic exposure to 0, 3 or 30 nM fluoxetine (Control, 3 nM FLU, and 30 nM FLU).
| Aromatase activity at metamorphosis | ||||
| (fmol/h/mg protein) | ||||
| Exposuregroup | Brain | Gonads | ||
| Females | Males | Females | Males | |
|
| 51±31 | 40±42 | 8.6±2.4 | 4.8±1.1 |
|
| 53±50 | 54±30 | 9.2±2.1 | 4.8±1.9 |
|
| 38±36 | 24±20 | 8.7±2.0 | 4.5±1.0 |
n = 8−10.
n = 10.
n = 10 ovary-kidney complexes.
n = 3–6 testis-kidney complexes.